Aims: We investigated the prognosis of patients with small-cell neuroendocrine carcinoma of the uterine cervix (SCNEC) in relation to treatment modalities. Methods: We retrospectively reviewed the medical records and pathological reports of 102 patients who were histologically diagnosed with SCNEC at 5 different institutes. Time to progression (TTP) and overall survival (OS) were analyzed for each treatment modality. Results: Of the patients with early-stage [International Federation of Obstetrics and Gynecology (FIGO) stage IB2 or below] SCNEC, 57.8 and 79.3% underwent radical hysterectomy followed by adjuvant therapy. In advanced-stage SCNEC, concurrent chemoradiation therapy was given to 51.4% of the patients. The overall recurrence rate was 51.6%. In early- and advanced-stage SCNEC, the TTP was not different (22.3 vs. 13.3 months, p = 0.104), but the OS was different (40.7 vs. 21.4 months, p = 0.029). Parametrial involvement and lymph vascular space invasion were found to be associated with an unfavorable prognosis. Interestingly, survival was the most unfavorable in patients with early-stage SCNEC who had never received chemotherapy. FIGO stage and use of chemotherapy were identified as independent prognostic factors in SCNEC patients. Conclusions: SCNEC requires systemic chemotherapy as part of the initial treatment, along with surgery or radiation, even in patients with early-stage disease.

Reagan JW, Hamonic MJ, Wentz WB: Analytical study of the cells in cervical squamous-cell cancer. Lab Invest 1957;6:241-250.
Tsunoda S, Jobo T, Arai M, Imai M, Kanai T, Tamura T, Watanabe J, Obokata A, Kuramoto H: Small-cell carcinoma of the uterine cervix: a clinicopathologic study of 11 cases. Int J Gynecol Cancer 2005;15:295-300.
Crowder S, Tuller E: Small cell carcinoma of the female genital tract. Semin Oncol 2007;34:57-63.
Appetecchia M, Benevolo M, Mariani L: Neuroendocrine small-cell cervical carcinoma. Eur J Obstet Gynecol Reprod Biol 2001;96:128-131.
Baykal C, Al A, Tulunay G, Bulbul D, Güler G, Ozer S, Küçükali T: High-grade neuroendocrine carcinoma of the cervix: a case report. Gynecol Obstet Invest 2005;59:207-211.
Sevin BU, Method MW, Nadji M, Lu Y, Averette HA: Efficacy of radical hysterectomy as treatment for patients with small cell carcinoma of the cervix. Cancer 1996;77:1489-1493.
Morris M, Gershenson DM, Eifel P, Silva EG, Mitchell MF, Burke TW, Wharton JT: Treatment of small cell carcinoma of the cervix with cisplatin, doxorubicin, and etoposide. Gynecol Oncol 1992;47:62-65.
Viswanathan AN, Deavers MT, Jhingran A, Ramirez PT, Levenback C, Eifel PJ: Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol 2004;93:27-33.
Gersell DJ, Mazoujian G, Mutch DG, Rudloff MA: Small-cell undifferentiated carcinoma of the cervix: a clinicopathologic, ultrastructural, and immunocytochemical study of 15 cases. Am J Surg Pathol 1988;12:684-698.
Loizzi V, Cormio G, Vicino M, Selvaggi L: Neoadjuvant chemotherapy: an alternative option of treatment for locally advanced cervical cancer. Gynecol Obstet Invest 2008;65:96-103.
Sheets EE, Berman ML, Hrountas CK, Liao SY, DiSaia PJ: Surgically treated, early-stage neuroendocrine small-cell cervical carcinoma. Obstet Gynecol 1988;71:10-14.
Lee SW, Nam JH, Kim DY, Kim JH, Kim KR, Kim YM, Kim YT: Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study. Int J Gynecol Cancer 2010;20:411-416.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the Unites States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
Morgan LC, Grayson D, Peters HE, Clarke CW, Peters MJ: Lung cancer in New South Wales: current trends and the influence of age and sex. Med J Aust 2000;172:578-582.
Walker AN, Mills SE, Taylor PT: Cervical neuroendocrine carcinoma: a clinical and light microscopic study of 14 cases. Int J Gynecol Pathol 1988;7:64-74.
Tateishi R, Wada A, Hayakawa K, Hongo J, Ishii S: Agyrophil cell carcinomas (apudomas) of the uterine cervix: light and eletron microscopic observations of 5 cases. Virchows Arch A Pathol Anat Histol 1975;366:257-274.
Haider K, Shahid RK, Finch D, Sami A, Ahmad I, Yadav S, Alvi R, Popkin D, Ahmed S: Extrapulmonary small cell cancer: a Canadian province's experience. Cancer 2006;107:2262-2269.
Ueda G, Yamasaki M: Neuroendocrine carcinoma of the uterus. Curr Top Pathol 1992;85:309-335.
Hoskins PJ, Wong F, Swenerton KD, Pike JA, Manji M, McMurtrie E, Acker B, Le Riche J: Small cell carcinoma of the cervix treated with concurrent radiotherapy, cisplatin, and etoposide. Gynecol Oncol 1995;56:218-225.
Abulafia O, Sherer DM: Adjuvant chemotherapy in stage IB neuroendocrine small cell carcinoma of the cervix. Acta Obstet Gynecol Scand 1995;74:740-744.
Chang TC, Lai CH, Tseng CJ, Hsueh S, Huang KG, Chou HH: Prognostic factors in surgically treated small cell cervical carcinoma followed by adjuvant chemotherapy. Cancer 1998;83:712-718.
Lee JM, Lee KB, Nam JH, Ryu SY, Bae DS, Park JT, Kim SC, Cha SD, Kim KR, Song SY, Kang SB: Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Anal Oncol 2008;19:321-326.
Zivanovic O, Leitao MM Jr, Park KJ, Zhao H, Diaz JP, Konner J, Alektiar K, Chi DS, Abu-Rustum NR, Aghajanian C: Small cell neuroendocrine carcinoma of the cervix: analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy. Gynecol Oncol 2009;112:590-593.
Simon GR, Turrisi A: Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(suppl 3):324S-339S.
Cohen JG, Kapp DS, Shin JY, Urban R, Sherman AE, Chen LM, Osann K, Chan JK: Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients. Am J Obstet Gynecol 2010;203:347.e1-e6.
Ferrandina G, Lucidi A, De Ninno M, Carbone A, Chiantera V, Morganti AG, Macchia G: Successful treatment of a young patient with locally advanced clear cell adenocarcinoma of the uterine cervix undergoing chemoradiation followed by radical surgery. Gynecol Obstet Invest 2014;77:64-67.
Meirovitz M, Sade S, Dreiher J, Shaco-Levy R: Is radical hysterectomy necessary in early cervical cancer? Gynecol Obstet Invest 2013;76:158-162.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.